# Pizarra — PT-pseudo_34647958aba3 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_34647958aba3
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 7.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.121 ng/mL²
  - PSA velocity: 2.45 ng/mL/yr
  - Prior PSA: 4.9 ng/mL
  - Prostate volume: 63.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.0 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis
  - Problem list / PMHx: Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 7.6 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 63 mL. DRE nodus. csPCa 0.00.

Vitals: weight 67 kg, height 179 cm, BMI 20.9, BP 128/95 mmHg, HR 83 bpm. Smoking: Ex-smoker (34 pack-yr, quit 2021).

Chief complaint: Clinical review requested due to escalating prostate-specific antigen values alongside established biopsy history.

History: This semi-retired harbour pilot, aged 65, has maintained routine monitoring since his initial biopsy uncovered low-grade disease. He shares a household with his spouse and experiences negligible lower urinary tract symptoms, scoring a mere 4 on the IPSS questionnaire. His medical routine includes periodic visits to a sleep clinic for suspected obstructive sleep apnoea, alongside a recently completed chest radiograph. Daily activities remain active, featuring regular gardening and a modest alcohol intake of approximately nine units per week. A complete cessation of tobacco occurred in 2021, marking the end of a 34 pack-year consumption. Osteoarthritic discomfort remains controlled with occasional paracetamol, while his appointment scheduling consistently favors mornings to accommodate public transit availability.

Physical examination: DRE — texture: firm; mobility: fixed; asymmetry: prominent nodule localized to the left peripheral zone. Systemic assessment reveals normal vital parameters without evidence of disseminated disease.

Patient info: harbour pilot (semi-retired); Married; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 9 units / week; exercise Gardening, no structured exercise; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Sleep clinic — suspected obstructive sleep apnoea; Radiology — chest X-ray (routine).
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.42 +/- 0.20   (95% CI 0.08-0.81)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.9 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=7.6, age=65.0, psad=0.121, dre_ord=1.0, vol=63.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (2.45 ng/mL/yr), the prior PSA (4.9 ng/mL), or the specific findings from the mpMRI report (PI-RADS 5) beyond the score itself, which might be context-dependent.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.42 +/- 0.20). This wide interval suggests high uncertainty. A failure mode is that the PI-RADS 5 combined with a rising PSA (from 4.9 to 7.6) might strongly push the decision towards biopsy, contradicting the prior's leaning towards 'no'. Another failure mode is that the prior ignores the clinical context of a prior positive biopsy, which might change the interpretation of the current findings.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant features (e.g., clinically significant lesion) that override the PI-RADS 5 score, it would shift the decision.
  <document> PSA history (trend) -> If the velocity (2.45 ng/mL/yr) is deemed highly concerning in context, it would increase the likelihood of biopsy.
  <document> previous GP / urology consultation notes -> These notes might clarify the initial low-grade disease diagnosis or the clinical significance of the prior biopsy result.
  <document> laboratory results (full panel) -> This panel might provide context on other markers that influence the risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_34647958aba3", "radiology_report": "Radboud University Medical Centre | Radiology Division | 20 February 2025 | Multiparametric MRI of the Prostate\n\nClinical indication: Evaluation of a 65-year-old gentleman with a PSA of 7.6 ng/mL and a history of a prior positive biopsy.\n\nFINDINGS:\nThe gland occupies a volume of 63.0 mL. T2-weighted sequences highlight a sharply demarcated hypointense area, roughly 18 mm in diameter, located in the left peripheral zone spanning the base through the mid-gland. Diffusion-weighted imaging shows intense restriction with corresponding ADC hypointensity. Early, focal enhancement is apparent on the dynamic contrast sequences. Capsular integrity remains intact with no seminal vesicle involvement or extracapsular spread. Pelvic lymph nodes appear normal.\n\nIMPRESSION:\nPI-RADS 5 lesion within the left peripheral zone.\nProstate volume 63.0 mL, PSAD 0.121 ng/mL/mL.\ncsPCa predicted probability 0.0."}

  **psa_trend**
  {"case_id": "PT-pseudo_34647958aba3", "psa_trend": [{"date": "Oct 2022", "val": 1.7}, {"date": "Dec 2023", "val": 2.6}, {"date": "Feb 2025", "val": 7.6}]}

  **previous_notes**
  {"case_id": "PT-pseudo_34647958aba3", "previous_notes": [{"date": "05 Sep 2023", "author": "Dr. K. Bakker (GP)", "text": "A laboratory draw in December 2023 recorded a PSA of 4.9 ng/mL, reflecting an incremental increase from the 4.3 ng/mL baseline noted in October 2022. Due to the history of a previous positive biopsy, a urology referral was initiated for comprehensive evaluation. During that visit, standard hematologic panels and a digital rectal assessment were completed."}]}

  **lab_results**
  {"case_id": "PT-pseudo_34647958aba3", "laboratory_results": [{"name": "PSA", "val": "7.6 ng/mL", "date": "13 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.22 ng/mL", "date": "13 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "13 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.9 g/dL", "date": "13 Jan 2025", "flag": ""}, {"name": "WBC", "val": "5.2 x10^9/L", "date": "13 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "222 x10^9/L", "date": "13 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "105 umol/L", "date": "13 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "13 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "16.2 nmol/L", "date": "13 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "74 U/L", "date": "13 Jan 2025", "flag": ""}, {"name": "LDH", "val": "175 U/L", "date": "13 Jan 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion within the left peripheral zone
  PSA velocity of 2.45 ng/mL/yr (from trend data)
  PSA has risen from 4.9 ng/mL (Dec 2023) to 7.6 ng/mL (Feb 2025)

  AGAINST sampling this patient now:
  csPCa predicted probability 0.0
  Prior biopsy was positive (implying prior diagnosis is established)

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which contradicts the statistical prior leaning towards 'NO BIOPSY'.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports sampling due to a PI-RADS 5 lesion in the left peripheral zone and a concerning PSA velocity of 2.45 ng/mL/yr. This finding is further supported by the PSA rising from 4.9 ng/mL to 7.6 ng/mL, which overrides the statistical prior suggesting deferral. The combination of high-risk imaging and rising PSA necessitates further tissue sampling to clarify the diagnosis.

Variables that carried weight: bx=decisive, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
